Cargando…

Pulmonary sarcoidosis complicated by rheumatoid arthritis in a patient presenting with progressive fibrosing interstitial lung disease and treated with nintedanib: a case report and literature review

Sarcoidosis is a multisystem disease with an unknown etiology and is characterized by the formation of noncaseating granulomas in the affected organs. We present the case of a 69-year-old male Japanese patient with bilateral hilar lymphadenopathy on chest radiographs for more than 10 years, left wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Ayana, Kamio, Koichiro, Takeno, Mitsuhiro, Terasaki, Yasuhiro, Taniuchi, Namiko, Sato, Junpei, Nishijima, Nobuhiko, Saito, Yoshinobu, Seike, Masahiro, Gemma, Akihiko, Azuma, Arata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989416/ https://www.ncbi.nlm.nih.gov/pubmed/36872912 http://dx.doi.org/10.1177/17534666231158279

Ejemplares similares

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)

Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
por: Schmid, Ulrike, et al.
Publicado: (2021)

Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
por: Westerink, Lotte, et al.
Publicado: (2022)

miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells
por: NISHIJIMA, NOBUHIKO, et al.
Publicado: (2016)

Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan
por: Urushiyama, Hirokazu, et al.
Publicado: (2022)

Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease
por: Deterding, Robin, et al.
Publicado: (2021)

Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial
por: Matteson, Eric L., et al.
Publicado: (2022)

Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
por: Cottin, Vincent, et al.
Publicado: (2022)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

Platinum‐combination chemotherapy with or without immune‐checkpoint inhibitor in patients with postoperative recurrent non‐small cell lung cancer previously treated with adjuvant platinum‐doublet chemotherapy: A multicenter retrospective study
por: Hisakane, Kakeru, et al.
Publicado: (2023)

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2015)

The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study
por: Cameli, Paolo, et al.
Publicado: (2022)

Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort?
por: Ho, Gen Nen, et al.
Publicado: (2023)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

Resolution of bleomycin-induced murine pulmonary fibrosis via a splenic lymphocyte subpopulation
por: Kamio, Koichiro, et al.
Publicado: (2018)

Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia – short term evaluation of safety and tolerability
por: Kamio, Koichiro, et al.
Publicado: (2014)

Progression of fibrosing interstitial lung disease
por: Wong, Alyson W., et al.
Publicado: (2020)

Management of Fibrosing Interstitial Lung Diseases
por: Maher, Toby M., et al.
Publicado: (2019)

Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2014)

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
por: Flaherty, Kevin R, et al.
Publicado: (2017)

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
por: Seibold, James R, et al.
Publicado: (2020)

The Burden of Progressive-Fibrosing Interstitial Lung Diseases
por: Cottin, Vincent, et al.
Publicado: (2022)

Management of patients with fibrosing interstitial lung diseases
por: Morrow, Lee E, et al.
Publicado: (2021)

Fibrosing interstitial lung diseases: knowns and unknowns
por: Cottin, Vincent, et al.
Publicado: (2019)

A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
por: Sugano, Teppei, et al.
Publicado: (2018)

Talaromycosis in a Patient on Nintedanib for Interstitial Lung Disease
por: Madgula, Anantha Sriharsha, et al.
Publicado: (2020)

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

Biomarkers of Fibroproliferative Healing in Fibrosing Idiopathic Interstitial Pneumonias
por: Vasakova, Martina, et al.
Publicado: (2012)

The natural history of progressive fibrosing interstitial lung diseases
por: Kolb, Martin, et al.
Publicado: (2019)

The natural history of progressive fibrosing interstitial lung diseases
por: Brown, Kevin K., et al.
Publicado: (2020)

Management and support of patients with fibrosing interstitial lung diseases
por: Barbera, Tyonn, et al.
Publicado: (2021)

Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases
por: Chen, Xianqiu, et al.
Publicado: (2021)

The Role of Radiology in Progressive Fibrosing Interstitial Lung Disease
por: Abu Qubo, Ahmad, et al.
Publicado: (2022)

Acute exacerbations of progressive-fibrosing interstitial lung diseases
por: Kolb, Martin, et al.
Publicado: (2018)

Role of imaging in progressive-fibrosing interstitial lung diseases
por: Walsh, Simon L.F., et al.
Publicado: (2018)

Burden of illness in progressive fibrosing interstitial lung disease
por: Singer, David, et al.
Publicado: (2022)

Evaluation of Fractional Analysis of Bronchoalveolar Lavage Combined with Cellular Morphological Features
por: Taniuchi, Namiko, et al.
Publicado: (2008)

Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer
por: Nishima, Shunichi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0fdgre5prnbgkkcbrqeoohhpr7